Literature DB >> 24154855

Characteristics and significance of colorectal cancer associated lymphoid reaction.

Juha P Väyrynen1, Sara A Sajanti, Kai Klintrup, Jyrki Mäkelä, Karl-Heinz Herzig, Tuomo J Karttunen, Anne Tuomisto, Markus J Mäkinen.   

Abstract

A subset of colorectal cancers (CRCs) exhibits so-called Crohn's like lymphoid reaction (CLR), an inflammatory reaction pattern that consists of numerous transmural lymphoid aggregates. However, the composition of these aggregates, their biological mechanisms and their prognostic significance are not well-defined. We analyzed two CRC cohorts (418 and 149 patients) and determined clinicopathological features including survival. A new method for evaluating CLR based on counting the areal density of the lymphoid follicles (CLR density) was adopted. Immune cell densities at intratumoral and peritumoral regions, as well as the composition of the lymphoid follicles, were studied by immunohistochemistry. We found that CLR comprised of lymphoid aggregates with no evidence of granuloma formation. High CLR density associated with lower tumor stage, lack of preoperative radiotherapy or chemoradiotherapy and deficient mismatch repair enzyme expression. CLR density had positive correlations with peritumoral and intratumoral densities of CD83(+) mature dendritic cells and T cells. High CLR density associated with better survival and had prognostic value that was independent of stage, Klintrup-Mäkinen score for peritumoral inflammation and the numbers of tumor infiltrating T cells. CLR density evaluation had excellent intraobserver and interobserver agreement. In conclusion, the results suggest that CLR contributes to the adaptive antitumor immunity. Quantitative evaluation of CLR density is a relevant prognostic indicator in CRC.
© 2013 UICC.

Entities:  

Keywords:  T lymphocyte; colorectal cancer; prognosis; tertiary lymphoid organ; tumor immunology

Mesh:

Year:  2013        PMID: 24154855     DOI: 10.1002/ijc.28533

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

1.  Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.

Authors:  Sara A Sajanti; Juha P Väyrynen; Päivi Sirniö; Kai Klintrup; Jyrki Mäkelä; Anne Tuomisto; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-11-14       Impact factor: 4.064

Review 2.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.

Authors:  Nazim Benzerdjeb; Peggy Dartigues; Vahan Kepenekian; Séverine Valmary-Degano; Eliane Mery; Gerlinde Avérous; Anne Chevallier; Marie-Hélène Laverriere; Irène Villa; Olivier Harou; Françoise Galateau Sallé; Laurent Villeneuve; Olivier Glehen; Sylvie Isaac; Juliette Hommell-Fontaine; Frédéric Bibeau
Journal:  Virchows Arch       Date:  2021-04-14       Impact factor: 4.064

4.  Histopathologic risk stratification of stage IIB colorectal cancer.

Authors:  Koji Komori; Takashi Kinoshita; Taihei Oshiro; Seiji Ito; Tetsuya Abe; Yoshiki Senda; Kazunari Misawa; Yuichi Ito; Norihisa Uemura; Seiji Natsume; Jiro Kawakami; Akira Ouchi; Masayuki Tsutsuyama; Takahiro Hosoi; Itaru Shigeyoshi; Tomoyuk Akazawa; Daisuke Hayashi; Hideharu Tanaka; Yasuhiro Shimizu
Journal:  Surg Today       Date:  2016-12-30       Impact factor: 2.549

5.  Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.

Authors:  Rin Yamada; Tatsuro Yamaguchi; Takeru Iijima; Rika Wakaume; Misato Takao; Koichi Koizumi; Tsunekazu Hishima; Shin-Ichiro Horiguchi
Journal:  Int J Clin Oncol       Date:  2018-01-11       Impact factor: 3.402

6.  Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.

Authors:  Katarzyna Jakubowska; Wojciech Kisielewski; Luiza Kańczuga-Koda; Mariusz Koda; Waldemar Famulski
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

7.  Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.

Authors:  Laura S Rozek; Stephanie L Schmit; Joel K Greenson; Lynn P Tomsho; Hedy S Rennert; Gad Rennert; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2016-05-12       Impact factor: 13.506

8.  Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Tsuyoshi Hamada; Mingyang Song; Annacarolina da Silva; Keisuke Kosumi; Mancang Gu; Yan Shi; Wanwan Li; Li Liu; Daniel Nevo; Kentaro Inamura; Yin Cao; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott J Rodig; Charles S Fuchs; Zhi Rong Qian; Jonathan A Nowak; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2017-10-16       Impact factor: 12.020

9.  High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression.

Authors:  Diana Costa Bento; Emma Jones; Syed Junaid; Justyna Tull; Geraint T Williams; Andrew Godkin; Ann Ager; Awen Gallimore
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

10.  Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1.

Authors:  Margaret R Dunne; Ciara Ryan; Bláthnaid Nolan; Miriam Tosetto; Robert Geraghty; Des C Winter; P Ronan O'Connell; John M Hyland; Glen A Doherty; Kieran Sheahan; Elizabeth J Ryan; Jean M Fletcher
Journal:  Front Oncol       Date:  2016-03-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.